eResearchTechnology and Pharma Bio-Research Sign Agreement to Deliver Integrated Cardiac Safety and Clinical Pharmacology Servic

eResearchTechnology and Pharma Bio-Research Sign Agreement to
Deliver Integrated Cardiac Safety and Clinical Pharmacology Services
Sixth Clinical Research Organization Enters into Digital Cardiac Safety
Monitoring Services Agreement with eResearchTechnology 


PHILADELPHIA, May 14  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc.
(eRT), , a leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, today announced it has entered into an
agreement with Pharma Bio-Research Group B.V. (PBR), a leading provider of
Phase I/IIA clinical trials and support services to the pharmaceutical and
biotechnology industries. This alliance, the sixth for eRT and second in
Europe, enables testing of new drug candidates in conjunction with emerging
international cardiac safety regulatory guidance and technical standards.

Under the agreement, Pharma Bio-Research will conduct clinical trials at its
Phase I unit in Zuidlaren, The Netherlands, while eRT will perform digital
collection, measurement, interpretation, review and distribution of cardiac
safety data through its EXPeRT workflow-enabled data handling technology. The
eRT technology is the first solution designed explicitly to meet emerging
international guidance and standards related to cardiac safety monitoring
services.

"Pharma Bio-Research has extensive clinical research experience since 1984,
including the conduct of more complex Phase I studies," said Robert Brown,
senior vice president of outsourcing partnerships for eRT. "Our alliance
presents a great opportunity for eRT to expand its Thorough Phase I ECG Study
partnership program within Europe and will help to meet increasing demand from
international drug development organizations for the ability to conduct
Thorough Phase I ECG studies in Europe. We are pleased to be announcing the
Pharma Bio-Research agreement and look forward to working closely with the
Pharma Bio-Research team to ensure effective execution of Thorough Phase I ECG
studies."

"eRT is the world leading provider of digital ECG collection, processing and
interpretation," said Willem Jan Drijfhout, Ph.D., Chief Scientific Officer of
PBR.  "As the European leader of complex phase I/IIA trials, the partnership
between PBR and eRT represents for us another opportunity to serve our clients
even better in their need for Thorough Phase I ECG studies, especially since
regulations are now demanding such studies to be conducted on a large scale. 
We look forward to intensifying our relationship with eRT under the current
agreement and are convinced that the professional staff of eRT fits well with
the high quality culture of PBR."

Based in Philadelphia, Pa., eResearchTechnology, Inc. (http://www.ert.com/) is
a provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis
and distribution of clinical data in all phases of clinical development.

Based in Zuidlaren, The Netherlands, Pharma Bio-Research Group B.V. is a full
service CRO with 140 total beds and offers the full range of services for phase
I/IIA clinical research, bioanalysis, biometrics and report writing with the
most competitive time lines, excellent quality, reliability and efficiency.
Since 1984, PBR has carried out more than 1,000 clinical studies and more than
2,000 bioanalytical studies.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. As a result, actual results may differ materially from any financial
outlooks stated herein.  Further information on potential factors that could
affect the company's financial results can be found in the company's reports on
Form 10-K and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, [phone]; or Matt

Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright